E

veryone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown — of individuals, companies, what have you — that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.

Winners:

Novo Nordisk scored a modest publicity coup by very publicly committing to limiting price hikes on its medicines to single-digit increases annually. The company is now the second big drug maker to do so, after Allergan. And while many people may not have read his note, Novo president Jakob Riis carefully and calmly used the opportunity to skewer pharmacy benefit managers and insurers, which the pharmaceutical industry is increasingly blaming for the rising cost of medicines.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.